Search research articles
Contact Us
Filters
Showing results (141-150 of 198) with videos related to
Page
of 20
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
July 21, 2004
The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients
Evagelos N Liberopoulos, George A Miltiadous, Marios Cariolou, et al.
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|
May 12, 2006
Serum potassium concentration in hyperglycemia of chronic dialysis
Mark Rohrscheib, Antonios H Tzamaloukas, Todd S Ing, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 3, 2005
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect
Haralampos J Milionis, Afroditi P Tambaki, Chrisa N Kanioglou, et al.
Lipids
|
April 3, 2013
Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes
Theodosios D Filippatos, Evangelos C Rizos, Vasilios Tsimihodimos, et al.
Current Vascular Pharmacology
|
February 26, 2010
Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia
Matilda Florentin, Alexadros D Tselepis, Moses S Elisaf, et al.
Metabolic Syndrome and Related Disorders
|
March 1, 2011
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂
Christos V Rizos, Evangelos N Liberopoulos, Constantinos C Tellis, et al.
Angiology
|
November 30, 2013
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes
Christos V Rizos, Evangelos N Liberopoulos, Kostas Tellis, et al.
Atherosclerosis
|
October 16, 2013
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia
Elisavet Moutzouri, Evangelos N Liberopoulos, Constantinos C Tellis, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
Theodosios D Filippatos, Vasilis Tsimihodimos, Michael Kostapanos, et al.
European Journal of Pharmacology
|
July 1, 2008
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia
Michael S Kostapanos, Haralampos J Milionis, Konstantinos G Lagos, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 198) with videos related to
Sort By:
Page
of 20
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
July 21, 2004
The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients
Evagelos N Liberopoulos, George A Miltiadous, Marios Cariolou, et al.
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|
May 12, 2006
Serum potassium concentration in hyperglycemia of chronic dialysis
Mark Rohrscheib, Antonios H Tzamaloukas, Todd S Ing, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 3, 2005
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect
Haralampos J Milionis, Afroditi P Tambaki, Chrisa N Kanioglou, et al.
Lipids
|
April 3, 2013
Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes
Theodosios D Filippatos, Evangelos C Rizos, Vasilios Tsimihodimos, et al.
Current Vascular Pharmacology
|
February 26, 2010
Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia
Matilda Florentin, Alexadros D Tselepis, Moses S Elisaf, et al.
Metabolic Syndrome and Related Disorders
|
March 1, 2011
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂
Christos V Rizos, Evangelos N Liberopoulos, Constantinos C Tellis, et al.
Angiology
|
November 30, 2013
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes
Christos V Rizos, Evangelos N Liberopoulos, Kostas Tellis, et al.
Atherosclerosis
|
October 16, 2013
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia
Elisavet Moutzouri, Evangelos N Liberopoulos, Constantinos C Tellis, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
Theodosios D Filippatos, Vasilis Tsimihodimos, Michael Kostapanos, et al.
European Journal of Pharmacology
|
July 1, 2008
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia
Michael S Kostapanos, Haralampos J Milionis, Konstantinos G Lagos, et al.
Page
of 20